1. Home
  2. MYND vs JSPR Comparison

MYND vs JSPR Comparison

Compare MYND & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mynd.ai Inc.

MYND

Mynd.ai Inc.

HOLD

Current Price

$0.42

Market Cap

15.6M

Sector

Real Estate

ML Signal

HOLD

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.46

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYND
JSPR
Founded
1998
2018
Country
United States
United States
Employees
N/A
22
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
14.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
MYND
JSPR
Price
$0.42
$0.46
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
1.5M
623.7K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.42
52 Week High
$1.15
$7.19

Technical Indicators

Market Signals
Indicator
MYND
JSPR
Relative Strength Index (RSI) 49.28 24.86
Support Level $0.29 N/A
Resistance Level $0.55 $1.06
Average True Range (ATR) 0.09 0.10
MACD -0.00 -0.03
Stochastic Oscillator 23.22 8.15

Price Performance

Historical Comparison
MYND
JSPR

About MYND Mynd.ai Inc.

Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: